Back HIV/AIDS HIV/AIDS Topics HIV Treatment

HIV Salvage Regimens Can Safely Omit NRTIs, Study Says

Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) can be safely omitted from HIV salvage therapy, investigators from Brown University report in the December 15, 2015 Annals of Internal Medicine. "Omitting NRTIs will reduce pill burden, cost, and toxicity in this patient population," the study authors conclude.

alt

Read more:

Top 10 HIV and Hepatitis Stories of 2015

Antiretroviral treatment for everyone living with HIV, expansion of pre-exposure prophylaxis (better known as PrEP) for HIV prevention, and access to interferon-free therapies for hepatitis C topped the HIV and viral hepatitis headlines this year and will continue to be major issues going into 2016. Here's a look back at some of our biggest news from 2015.

alt

Read more:

7. Simplified Dolutegravir Therapy Looks Promising

The potent HIV integrase inhibitor dolutegravir (Tivicay) taken with a single well-tolerated NRTI fully suppressed viral load in people starting antiretroviral therapy for the first time, while dolutegravir monotherapy was able to keep HIV suppressed in most treatment-experienced people who started with undetectable viral load, according to studies presented at the European AIDS Conference in October.

alt

Read more:

1. Treat Everyone Living with HIV

In September the World Health Organization released updated guidelines calling for antiretroviral therapy (ART) for everyone diagnosed with HIV regardless of CD4 T-cell count, as well as pre-exposure prophylaxis for people at substantial risk of infection. WHO estimates that the recommendations, if widely adopted, could avert 21 million deaths and prevent 28 million new infections worldwide by 2030.

alt

Read more:

8. Long-term HIV Remission and Post-Treatment Control

A young woman who was infected with HIV at birth and received very early antiretroviral therapy (ART) as a baby has maintained a viral load below the limit of detectability of standard tests for more than 12 years after stopping treatment, shedding more light on "post-treatment control" as a potential functional cure strategy.

alt

Read more:

6. New TAF Version of Tenofovir Approved in Combo Pill

In November the U.S. Food and Drug Administration announced the approval of Gilead Sciences' Genvoya, a new single-tablet regimen containing the integrase inhibitor elvitegravir, the booster cobicistat, emtricitabine, and tenofovir alafenamide or TAF -- a new formulation that is easier on the kidneys and bones than the older tenofovir disoproxil fumarate (TDF).

alt

Read more:

San Francisco AIDS Foundation Opens Strut Health and Wellness Center2

TEXT

alt

Read more: